← Human Trials & Peer-Reviewed Studies
Effect of growth hormone on hepatic cytochrome P450 activity in healthy elderly men.
Plain-language guide to PMID 11907490 (2002): double-blind randomized controlled trial of Exogenous HGH, sermorelin & older GHRPs (why they're passed over) in 30 men.
Key Facts
- PMID
- 11907490
- Journal
- Clinical pharmacology and therapeutics
- Year
- 2002
- Study type
- Randomized Controlled Trial
- Authors
- Jürgens G et al. (6 authors)
- DOI
- 10.1067/mcp.2002.121373
What This Study Did, in Plain Language
What Was Tested
Researchers studied Exogenous HGH, sermorelin & older GHRPs (why they're passed over) in this randomized controlled trial publication.
Their objective was to study the effect of recombinant human growth hormone (rhGH) on hepatic cytochrome P450 (CYP) activity in 30 healthy elderly men.
Who Took Part
The abstract describes 30 men taking part.
The age groups tagged for this paper are older adults and people over 80, men only.
How the Study Was Run
The design is described as randomized, double-blind, placebo-controlled and parallel-group.
The men were allocated by chance, so the Exogenous HGH, sermorelin & older GHRPs (why they're passed over) group and the comparison group should start out alike.
Neither the men nor the staff measuring them knew who was on Exogenous HGH, sermorelin & older GHRPs (why they're passed over), so expectations could not easily colour the readings.
Some men received a placebo instead of Exogenous HGH, sermorelin & older GHRPs (why they're passed over), giving a reference point.
The Exogenous HGH, sermorelin & older GHRPs (why they're passed over) group and the comparison group ran side by side rather than switching.
What Was Measured
PubMed files the paper under topics including Anti-Inflammatory Agents, Non-Steroidal, Antipyrine, Cytochrome P-450 Enzyme System, Growth Hormone, Hydrocortisone, Insulin-Like Growth Factor I and Liver.
What This Means in Plain Language
The paper is a randomized, double-blind and placebo-controlled study of Exogenous HGH, sermorelin & older GHRPs (why they're passed over) in 30 men.
With fewer than 40 people, it is a small study, so it is better read as an early signal for further research than as a settled answer.
The abstract goes on to report its results in about 5 sentences; this page does not restate them, so read the paper for the findings and their limits.
The publication is from 2002 (Clinical pharmacology and therapeutics), a journal based in United States.
More context: the Exogenous HGH, sermorelin & older GHRPs (why they're passed over) compound page, all human trials.
Our Notes on the Compound
Exogenous HGH, sermorelin & older GHRPs (why they're passed over): Constant levels suppress the body's own GHRH, raise somatostatin and dull pituitary response.
Related Pages
Source: PubMed record. This explanation is written by PeptideWhiz from the public record. For research and education only. Not medical advice; no dosing information is given.